Literature DB >> 7805453

Lymph node metastasis in stage I ovarian carcinoma.

J H Lang1.   

Abstract

One hundred and sixteen cases of stage I ovarian cancer from 6 hospitals in China were investigated for their lymph node metastasis from September, 1982 to April 1991. Of them, 70 had epithelial tumor, 36 malignant germ cell tumor, 8 gonadal stroma, and 2 undifferentiated tumor. Ovarian tumor confined to one ovary (stage Ia) in 89 patients, both ovaries involved (stage IIb) in 6, and documented stage Ic in 21. Systemic lymphadenectomy involving all pelvic groups of node together with aortic lymph node was accomplished in 82 patients. In the remaining 34 patients, pelvic lymph node dissection was performed. The incidence of lymphatic metastasis was 10.3% in this series. Serous cystadenocarcinoma was the most common lesion. All patients were followed up for at least half year. The mortality rate in patients with and without lymph node metastasis was 8.3% and 2.8% respectively. The clinical significance of retroperitoneal lymphadenectomy in early ovarian carcinoma was discussed.

Entities:  

Mesh:

Year:  1994        PMID: 7805453

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  3 in total

1.  Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion.

Authors:  Eun-Ju Lee; Cristian Mircean; Ilya Shmulevich; Huamin Wang; Jinsong Liu; Antti Niemistö; John J Kavanagh; Je-Ho Lee; Wei Zhang
Journal:  Mol Cancer       Date:  2005-02-02       Impact factor: 27.401

2.  Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma.

Authors:  Yu Zhao; Shu Wang; Yi-Min Qu; Yu-Ting Ji; Keng Shen; Jing He Lang
Journal:  J Ovarian Res       Date:  2017-09-18       Impact factor: 4.234

3.  Prognostic factors in early-stage ovarian cancer.

Authors:  Germana Tognon; Mario Carnazza; Monica Ragnoli; Stefano Calza; Federico Ferrari; Angela Gambino; Valentina Zizioli; Sara Notaro; Benedetta Sostegni; Enrico Sartori
Journal:  Ecancermedicalscience       Date:  2013-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.